Validea Detailed Fundamental Analysis

According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) receives a 77% rating based on Partha Mohanram's P/B Growth Investor model, which favors low book-to-market stocks exhibiting sustained growth characteristics. The model, which assesses metrics such as return on assets and cash flow, suggests "some interest" in the stock, though it fails tests related to advertising and R&D spending relative to assets. Mohanram's research identifies criteria to distinguish successful growth stocks from those that falter, challenging traditional views on growth investing.

Analysis

Thermo Fisher Scientific Inc. (TMO) has been evaluated by Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, receiving a 77% rating; this score approaches the 80% threshold that typically signifies 'some interest' from the model, while scores above 90% indicate strong interest. TMO, a large-cap growth stock in the Medical Equipment & Supplies industry, passed several fundamental tests within this model, including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, Cash Flow from Operations to Assets versus Return on Assets, Return on Assets Variance, Sales Variance, and Capital Expenditures to Assets. However, the company failed criteria related to Advertising to Assets and Research and Development to Assets. Mohanram's academically-derived model aims to identify growth stocks with sustained upward potential by analyzing financial statement criteria. Despite the score being slightly below the 'some interest' benchmark for this specific model, the general sentiment signals for TMO are moderately positive, reflecting its strengths in other fundamental areas.

Key Decisions for Investors

• Investors should acknowledge TMO's solid performance on multiple core financial metrics such as return on assets and operational cash flow, which are favorable points under the P/B Growth Investor model.
• It is crucial to scrutinize TMO's failure to meet the model's criteria for Advertising to Assets and Research and Development to Assets, as these could be significant for sustaining long-term growth, especially within the innovation-reliant Medical Equipment & Supplies sector.
• Given the 77% rating approaches the 80% 'some interest' threshold, investors might consider this a prompt for deeper due diligence, particularly focusing on the company's strategic rationale for current R&D and advertising spend and its potential impact on future growth trajectories.